心力衰竭中的呼吸暂停与表型导向治疗:第一部分:阻塞性睡眠呼吸暂停
睡眠呼吸障碍(包括OSA和中枢性睡眠呼吸暂停)在射血分数降低和保留的心衰患者中均高度流行。OSA的急性病理生物学效应包括交感神经过度激活、氧化应激和炎症,可能导致左室功能进行性恶化、反复住院和死亡率过高。大量观察性研究和少数小型随机对照试验显示治疗可改善SDB的多种心血管后果,但尚无长期随机对照试验证明治疗OSA可改善心衰患者生存;一项纳入心衰患者的持续气道正压通气治疗OSA的试验显示临床结局无改善,但该试验存在文献中广泛讨论的重要缺陷。随着持续气道正压通气作为心衰中SDB唯一治疗的地位受到质疑,需要对该领域长期公认的概念进行批判性审视。本综述旨在将近期进展整合为基于表型的OSA合并心衰管理方法。
要点
- OSA在无症状和有症状的射血分数降低及保留的心衰患者中均高度流行。
- OSA的急性病理生物学后果包括交感神经过度激活、氧化应激和炎症,可能致左室功能进行性恶化、反复住院和死亡率过高。
- 大量观察性研究和少数小型随机对照试验显示治疗SDB可改善多种心血管后果,但无长期随机对照试验证明治疗OSA可改善心衰患者生存。
- 一项纳入心衰患者的持续气道正压通气治疗OSA的试验显示临床结局无改善,但该试验存在文献中广泛讨论的重要缺陷。
- 综述提出基于表型的方法来管理心衰中的OSA,因持续气道正压通气作为唯一治疗的地位日益受到质疑。
适用人群与场景
- 心衰患者,包括无症状和有症状的射血分数降低的心衰患者,以及射血分数保留的心衰患者。
研究设计与关键结果
- 综述指出,睡眠呼吸障碍(包括OSA和中枢性睡眠呼吸暂停)在心衰患者中高度流行。
- OSA的急性病理生物学后果包括交感神经过度激活、氧化应激和炎症,最终可能导致左室功能进行性恶化、反复住院和死亡率过高。
- 大量观察性研究和少数小型随机对照试验显示,治疗SDB可改善多种心血管后果。
- 尚无长期随机对照试验显示治疗OSA可改善心衰患者生存。
- 一项纳入心衰患者的持续气道正压通气治疗OSA的试验显示临床结局无改善,但该试验存在文献中广泛讨论的重要缺陷。
证据类型、等级与局限
- 证据类型:综述。
对床旁实践的改变
- 综述提出基于表型的OSA合并心衰管理方法,因持续气道正压通气作为唯一治疗的地位日益受到质疑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sleep-disordered breathing (SDB), including OSA and central sleep apnea, is highly prevalent in patients with heart failure (HF). Multiple studies have reported this high prevalence in asymptomatic as well as symptomatic patients with reduced left ventricular ejection fraction (HFrEF), as well as in those with HF with preserved ejection fraction. The acute pathobiologic consequences of OSA, including exaggerated sympathetic activity, oxidative stress, and inflammation, eventually could lead to progressive left ventricular dysfunction, repeated hospitalization, and excessive mortality. Large numbers of observational studies and a few small randomized controlled trials have shown improvement in various cardiovascular consequences of SDB with treatment. There are no long-term randomized controlled trials to show improved survival of patients with HF and treatment of OSA. One trial of positive airway pressure treatment of OSA included patients with HF and showed no improvement in clinical outcomes. However, any conclusions derived from this trial must take into account several important pitfalls that have been extensively discussed in the literature. With the role of positive airway pressure as the sole therapy for SDB in HF increasingly questioned, a critical examination of long-accepted concepts in this field is needed. The objective of this review was to incorporate recent advances in the field into a phenotype-based approach to the management of OSA in HF.
参考来源
- Javaheri S, Brown LK, Abraham WT, et al. Apneas of Heart Failure and Phenotype-Guided Treatments: Part One: OSA. Chest. 2019. PMID: 31047953. doi:10.1016/j.chest.2019.02.407
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。